Cargando…

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung

Adenosquamous carcinoma (ASC) of the lung is a relatively rare tumor with strong aggressiveness and poor prognosis. The analysis of mutational signatures is becoming routine in cancer genomics and has implications for pathogenesis, classification, and prognosis. However, the distribution of mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongbiao, Liu, Jun, Zhu, Sujuan, Miao, Kun, Li, Zhifeng, Qi, Xiaofang, Huang, Lujia, Guo, Lijie, Wang, Yan, Cai, Yuyin, Lin, Yingcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518956/
https://www.ncbi.nlm.nih.gov/pubmed/36185247
http://dx.doi.org/10.3389/fonc.2022.945843
_version_ 1784799300258103296
author Wang, Hongbiao
Liu, Jun
Zhu, Sujuan
Miao, Kun
Li, Zhifeng
Qi, Xiaofang
Huang, Lujia
Guo, Lijie
Wang, Yan
Cai, Yuyin
Lin, Yingcheng
author_facet Wang, Hongbiao
Liu, Jun
Zhu, Sujuan
Miao, Kun
Li, Zhifeng
Qi, Xiaofang
Huang, Lujia
Guo, Lijie
Wang, Yan
Cai, Yuyin
Lin, Yingcheng
author_sort Wang, Hongbiao
collection PubMed
description Adenosquamous carcinoma (ASC) of the lung is a relatively rare tumor with strong aggressiveness and poor prognosis. The analysis of mutational signatures is becoming routine in cancer genomics and has implications for pathogenesis, classification, and prognosis. However, the distribution of mutational signatures in ASC patients has not been evaluated. In this study, we sought to reveal the landscape of genomic mutations and mutational signatures in ASC. Next-generation sequencing (NGS) technology was used to retrieve genomic information for 124 ASC patients. TP53 and EGFR were the most prevalent somatic mutations observed, and were present in 66.9% and 54.8% of patients, respectively. CDKN2A (21%), TERT (21%), and LRP1B (18.5%) mutations were also observed. An analysis of gene fusion/rearrangement characteristics revealed a total of 64 gene fusions. The highest frequency of variants was determined for ALK fusions, with six ALK-EML4 classical and two intergenic ALK fusions, followed by three CD74-ROS1 fusions and one ROS1-SYN3 fusion. EGFR 19del (45.6%), and EGFR L858R (38.2%) and its amplification (29.4%) were the top three EGFR mutations. We extracted mutational signatures from NGS data and then performed a statistical analysis in order to search for genomic and clinical features that could be linked to mutation signatures. Amongst signatures cataloged at COSMIC, the most prevalent, high-frequency base changes were for C > T; and the five most frequent signatures, from highest to lowest, were 2, 3, 1, 30, and 13. Signatures 1 and 6 were determined to be associated with age and tumor stage, respectively, and Signatures 22 and 30 were significantly related to smoking. We additionally evaluated the correlation between tumor mutational burden (TMB) and genomic variations. We found that mutations ARID2, BRCA1, and KEAP1 were associated with high TMB. The homologous recombination repair (HRR) pathway-related gene mutation displayed a slightly higher TMB than those without mutations. Our study is the first to report comprehensive genomic features and mutational signatures in Chinese ASC patients. Results obtained from our study will help the scientific community better understand signature-related mutational processes in ASC.
format Online
Article
Text
id pubmed-9518956
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95189562022-09-29 Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung Wang, Hongbiao Liu, Jun Zhu, Sujuan Miao, Kun Li, Zhifeng Qi, Xiaofang Huang, Lujia Guo, Lijie Wang, Yan Cai, Yuyin Lin, Yingcheng Front Oncol Oncology Adenosquamous carcinoma (ASC) of the lung is a relatively rare tumor with strong aggressiveness and poor prognosis. The analysis of mutational signatures is becoming routine in cancer genomics and has implications for pathogenesis, classification, and prognosis. However, the distribution of mutational signatures in ASC patients has not been evaluated. In this study, we sought to reveal the landscape of genomic mutations and mutational signatures in ASC. Next-generation sequencing (NGS) technology was used to retrieve genomic information for 124 ASC patients. TP53 and EGFR were the most prevalent somatic mutations observed, and were present in 66.9% and 54.8% of patients, respectively. CDKN2A (21%), TERT (21%), and LRP1B (18.5%) mutations were also observed. An analysis of gene fusion/rearrangement characteristics revealed a total of 64 gene fusions. The highest frequency of variants was determined for ALK fusions, with six ALK-EML4 classical and two intergenic ALK fusions, followed by three CD74-ROS1 fusions and one ROS1-SYN3 fusion. EGFR 19del (45.6%), and EGFR L858R (38.2%) and its amplification (29.4%) were the top three EGFR mutations. We extracted mutational signatures from NGS data and then performed a statistical analysis in order to search for genomic and clinical features that could be linked to mutation signatures. Amongst signatures cataloged at COSMIC, the most prevalent, high-frequency base changes were for C > T; and the five most frequent signatures, from highest to lowest, were 2, 3, 1, 30, and 13. Signatures 1 and 6 were determined to be associated with age and tumor stage, respectively, and Signatures 22 and 30 were significantly related to smoking. We additionally evaluated the correlation between tumor mutational burden (TMB) and genomic variations. We found that mutations ARID2, BRCA1, and KEAP1 were associated with high TMB. The homologous recombination repair (HRR) pathway-related gene mutation displayed a slightly higher TMB than those without mutations. Our study is the first to report comprehensive genomic features and mutational signatures in Chinese ASC patients. Results obtained from our study will help the scientific community better understand signature-related mutational processes in ASC. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9518956/ /pubmed/36185247 http://dx.doi.org/10.3389/fonc.2022.945843 Text en Copyright © 2022 Wang, Liu, Zhu, Miao, Li, Qi, Huang, Guo, Wang, Cai and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Hongbiao
Liu, Jun
Zhu, Sujuan
Miao, Kun
Li, Zhifeng
Qi, Xiaofang
Huang, Lujia
Guo, Lijie
Wang, Yan
Cai, Yuyin
Lin, Yingcheng
Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung
title Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung
title_full Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung
title_fullStr Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung
title_full_unstemmed Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung
title_short Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung
title_sort comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518956/
https://www.ncbi.nlm.nih.gov/pubmed/36185247
http://dx.doi.org/10.3389/fonc.2022.945843
work_keys_str_mv AT wanghongbiao comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT liujun comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT zhusujuan comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT miaokun comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT lizhifeng comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT qixiaofang comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT huanglujia comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT guolijie comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT wangyan comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT caiyuyin comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung
AT linyingcheng comprehensiveanalysesofgenomicfeaturesandmutationalsignaturesinadenosquamouscarcinomaofthelung